If you have been reading about alpha-MSH and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-13. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
=== Presentation === The clinical manifestations of this disease are anaemia, jaundice, fever, hepatomegaly, splenomegaly, lymphadenopathy, haematochezia and persistent bleeding from the nose, oral cavity and the tips, margins and outer surface of the pinnae. Other features include lethargy, loss of appetite, weakness, weight loss, dyspnoea, petechiae and haematemesis.
Evelyn Greechan, Senior Traffic Warden, City of Glasgow Police. For services to Road Safety. Ian Greenlaw, Support Grade Band 1, Her Majesty's Customs and Excise. Brian Gregory, Facilities Manager, Sussex Police. For services to the Police. Sylvia Gladys Grove, Office Support Grade Band 2, Home Office. Alan Joseph Gruar, Training Manager, Lucas Aerospace, Wolverhampton Training Centre, LucasVarity plc. For services to Training. Leslie Gurney. For services to the community in Stockport, Cheshire. Jessie Haggarty. For services to Highland Dancing. Jonathan Ian Hague, Detective Inspector, Metropolitan Police. For services to the Police. Alfred Hall. For services to the World Ploughing Organisation. Arthur Charles Hall. For services to the community in Walton-on-Thames, Surrey. Eileen Hall, Administrative Officer, Department of Social Security. Edna Hilda Knight Hallatt, Governor, Newcastle-under-Lyme School, Staffordshire. For services to Education. Mae Hamilton, Administrative Officer, Home Office. Brenda Margaret Hancock, lately Personal Secretary, Health and Safety Executive, Department of the Environment Angela Kathenne Hanley, Training Manager, First Aid Centre, London Transport. For services to Public Transport. Hilda Harding. For services to Mind and to the Elderly and Disadvantaged in Sutton, Surrey. Anthony Shannon Harman. For services to Agriculture and to the British Charolais Cattle Society. Susan Gladys Harper, Practice Nurse (Sister), Roslin Medical Centre, Midlothian. For services to Health Care. David Harris.
Spironolactone, sold under the brand name Aldactone among others, is classed as a diuretic medication. It can be used to treat fluid build-up due to liver disease or kidney disease. It is also used to reduce risk of disease progression, hospitalization, and death due to some types of heart failure. Other uses include acne and excessive hair growth in women, low blood potassium that does not improve with supplementation, high blood pressure that is difficult to treat, and early puberty in boys. It is also used to block the effects of testosterone as a part of feminizing hormone therapy. Spironolactone is usually available in tablets, taken by mouth, though topical forms are also available. Common side effects include electrolyte abnormalities, particularly high blood potassium, nausea, vomiting, headache, rashes, and a decreased desire for sex. In those with liver or kidney problems, extra care should be taken. If taken during pregnancy, some animal studies suggest that spironolactone may affect the development of sex organs in babies. While this has not occurred in the few human studies available, women who are pregnant or considering pregnancy should discuss spironolactone use with their doctor due to the theoretical risk. Spironolactone is a steroid that blocks the effects of the hormones aldosterone, and to a lesser degree, testosterone, causing some estrogen-like effects. Spironolactone belongs to a class of medications known as potassium-sparing diuretics. Spironolactone was discovered in 1957, and was introduced in 1959.
Russian missiles struck Pavlohrad, destroying "dozens" of houses, other buildings and wounding thirty four. Kyiv also came under attack, however no damage or losses were reported. Ukraine claimed to have shot down fifteen of the eighteen missiles fired. Pavlohrad was a logistical and railway hub with a Russian-installed official, Vladimir Rogov, claiming that the attacks were aimed at railway infrastructure and fuel depots in the city. Russian shelling in Kherson killed one person. Russia announced the removal of Col. Gen. Mikhail Mizintsev from his post as deputy defence minister in charge of logistics. In Russia's Bryansk Oblast, bordering Ukraine, a freight train derailed after an explosive device detonated along the Bryansk-Unecha railway line. U.S. National Security Council spokesman John Kirby, said that the US estimated that the Russians had suffered 100,000 casualties, including over 20,000 dead, during the Battle of Bakhmut alone since December 2022. He also stated that half of these losses were from the Wagner Group. Yevgeny Prigozhin, head of Wagner PMC, said that his forces were only getting a third of ammunition they needed.
Sources: en.wikipedia.org
== Analogs == Structural analogs of desmethylprodine with different N-substituents than a methyl group on the piperidine have been investigated. Several of these have significantly greater in vitro potency compared to desmethylprodine.
where Fi is blood flow (noted Q in the Figure above), Cart incoming arterial blood concentration, Pi the tissue over blood partition coefficient and Vi the volume of compartment i. A complete set of differential equations for the 7-compartment model shown above could therefore be given by the following table:
=== India === G. N. Singh, India's top drug regulator, said in a 2014 interview: "If I have to follow U.S. standards in inspecting facilities supplying to the Indian market, […] we will have to shut almost all of those." According to Outsourcing Pharma in 2012, 75% of counterfeit drugs supplied worldwide had some origins in India, followed by 7% from Egypt and 6% from China. In 2009, the Central Drug Standards Control Organisation (CDSCO), the drug regulatory authority of India conducted a nationwide survey, and announced that of "24,000 samples [that] were collected from all over India and tested. It was found that only 11 samples or 0.046% were spurious." In 2017 a similar survey found 3.16% of the medicines sampled were substandard and 0.0245% were fake. Those more commonly prescribed are probably more often faked. In 2017, industry body ASSOCHAM wrote in the paper "Fake and Counterfeit Drugs In India –Booming Biz" that fake drugs constitute US$4.25 billion of the total US$14–17 billion of domestic drug market. Around 25% of India's drugs are fake, counterfeit or substandard. If the fake drugs market grows at the current rate of 25%, it will cross the US$10 billion mark by 2017. Trade in fake drugs is driven caused by lack of adequate regulations, shortage of drug inspectors and a lack of lab facilities to check the purity of drugs. Other key factors include storage of spurious drugs by chemists, weaknesses in drug distribution system, lack of awareness among consumers and lack of law enforcement.
== Life cycle == Blastocystis hominis has a multistage life cycle and is highly adaptable to a variety of host environments. The illness develops when the cyst form is consumed by contaminated food or water. When the cyst enters the colon, it grows into a vacuolar form, which is the key diagnostic stage usually seen in stool samples. The organism has two separate transmission patterns: external transmission and self-infection. During external transmission, thick-walled cysts discharged in feces can survive in the environment and stay infectious for long periods. These environmentally resistant cysts enhance transmission between hosts via the fecal-oral pathway. In autoinfection, thin-walled cysts form from the vacuolar form and excyst within the intestine, sustaining infection in the same host. The vacuolar shape can also transform into a multi-vacuolar. It may eventually transform into an amoeboid. The amoeboid stage, while less prevalent, is thought to play a role in pathogenicity. Binary fission is the principal mode of reproduction, occurring in both vacuolar and amoeboid forms. Under stress conditions, such as unfavorable environmental factors or host immunological responses, the organism can generate pre-cyst stages that eventually develop into mature cysts. This complicated life cycle, with its numerous physical forms, helps the organism colonize and spread to a wide range of host species.
== Research == Polymyxins are used to neutralize or absorb LPS contaminants in samples, for example in immunological experiments. Minimization of LPS contamination can be important because LPS can evoke strong reactions from immune cells, distorting experimental results. By increasing permeability of the bacterial membrane system, polymyxin is also used in clinical work to increase the release of secreted toxins, such as Shiga toxin, from Escherichia coli. The global problem of advancing antimicrobial resistance has led to a renewed interest in their use.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.